Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV89.6

Virology

Volumn 308, Issue 1, 2003, Pages 178-190

  Ambrose, Zandrea ^a,f   Thompson, Jannelle ^a   Larsen, Kay ^a   Kuller, Larene ^a   Panicali, Dennis L ^b   Clements, John D ^c   Agy, Michael ^a   Montefiori, David C ^d   Hu, Shiu Lok ^a   Bosch, Marnix L ^a,e,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Therion Biologics Corporation   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Northwest Biotherapeutics Inc   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HIV; Immunity; Immunization; Macaque; Mucosal; Prime boost; SHIV; Vaccine

Indexed keywords

CD8 ANTIGEN; ENTEROTOXIN; GAG PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA NEMESTRINA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; VACCINIA; VACCINIA VIRUS;

EID: 0344406249     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00027-8     Document Type: Article

References (47)

1. Ambrose Z., Larsen K., Thompson J., Stevens Y., Finn E., Hu S.L., Bosch M.L. Evidence for early local viral replication and local production of antiviral immunity upon mucosal simian-human immunodeficiency virus SHIV(89.6) infection in Macaca nemestrina. J. Virol. 75:2001;8589-8596.
2. Baba T.W., Jeong Y.S., Pennick D., Bronson R., Greene M.F., Ruprecht R.M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 267:1995;1820-1825.
3. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206.
4. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Pennick D., Bronson R., Greene M.F., McClure H.M., Martin L.N., Ruprecht R.M. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5:1999;194-203.
5. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339.
6. Belyakov I.M., Ahlers J.D., Clements J.D., Strober W., Berzofsky J.A. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J. Immunol. 165:2000;6454-6462.
7. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., Watkins D.I., Allen T.M., Settle A., Altman J., Woodward R., Markham P.D., Clements J.D., Franchini G., Strober W., Berzofsky J.A. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7:2001;1320-1326.
8. Bogers W.M.J.M., Cheng-Mayer C., Montelaro R.C. Developments in preclinical AIDS vaccine efficacy models. AIDS. 14:2000;S141-S151.
9. Buge S.L., Richardson E., Alipanah S., Markham P., Cheng S., Kalyan N., Miller C.J., Lubeck M., Udem S., Eldridge J., Robert-Guroff M. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:1997;8531-8541.
10. Cardenas-Freytag L., Cheng E., Mayeux P., Domer J.E., Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immunol. 67:1999;826-833.
11. Chertova E., Bess J.W. Jr., Crise B.J., Sowder I.R., Schaden T.M., Hilburn J.M., Hoxie I.A., Benveniste R.E., Lifson J.D., Henderson L.E., Arthur L.O. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:2002;5315-5325.
12. Choi A.H., McNeal M.M., Flint J.A., Basu M., Lycke N.Y., Clements J.D., Bean J.A., Davis H.L., McCluskie M.J., VanCott J.L., Ward R.L. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine. 20:2002;1733-1740.
13. Chong C., Friberg M., Clements J.D. LT(R192G), a nontoxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 16:1998;732-740.
14. Crawford J.M., Earl P.L., Moss B., Reimann K.A., Wyand M.S., Manson K.H., Bilska M., Zhou J.T., Pauza C.D., Parren P.W., Burton D.R., Sodroski J.G., Letvin N.L., Montefiori D.C. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73:1999;10199-10207.
15. Dailey P.J., Zamroud M., Kelso R., Kolberg J., Urdea M. Quantitation of simian immunodeficiency virus (SIV) RNA in plasma of acute and chronically infected macaques using a branched DNA (bDNA) signal amplification assay. J. Med. Primatol. 24:1995;209.
16. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immunol. 63:1995;1617-1623.
17. Freytag L.C., Clements J.D. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236:1999;215-236.
18. Hu S.L., Abrams K., Barber G.N., Moran P., Zarling J.M., Langlois A.J., Kuller L., Morton W.R., Benveniste R.E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 255:1992;456-459.
19. Igarashi T., Shibata R., Hasebe F., Ami Y., Shinohara K., Komatsu T., Stahl-Hennig C., Petry H., Hunsmann G., Kuwata T., al e. Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res. Hum. Retroviruses. 10:1994;1021-1029.
20. Israel Z.R., Gettie A., Ishizaka S.T., Mishkin E.M., Staas J., Gilley R., Montefiori D., Marx P.A., Eldridge J.H. Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum; vaginal, and tracheal antibody responses in female rhesus macaques. AIDS Res. Hum. Retroviruses. 15:1999;1121-1136.
21. Joag S.V., Li Z., Foresman L., Stephens E.B., Zhao L.-J., Adany I., Pinson D.M., McClure H.M., Narayan O. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J. Virol. 70:1996;3189-3197.
22. Joag S.V., Liu Z.Q., Stephens E.B., Smith M.S., Kumar A., Li Z., Wang C., Sheffer D., Jia F., Foresman L., Adany I., Lifson J., McClure H.M., Narayan O. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 72:1998;9069-9078.
23. Johnson R.P., Desrosiers R.C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10:1998;436-443.
24. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., Yang J., Monefiori D.C., Montelaro R., Wyand M.S., Desrosiers R.C. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge inverse relationship of degree of protection with level of attenuation . J. Virol. 73:1999;4952-4961.
25. Kuller L., Thompson J., Watanabe R., Iskandriati D., Alpers C.E., Morton W.R., Agy M.B. Mucosal antibody expression following rapid SIV(Mne) dissemination in intrarectally infected Macaca nemestrina. AIDS Res. Hum. Retroviruses. 14:1998;1345-1356.
26. Lee L.H., Burg E., Baqar S., Bourgeois A.L., Burr D.H., Ewing C.P., Trust T.J., Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect. Immunol. 67:1999;5799-5805.
27. Li J., Lord C.I., Haseltine W., Letvin N.L., Sodroski J. Infection of cynamolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune Defic. Syndr. 5:1992;639-646.
28. Luciw P.A., Pratt-Lowe E., Shaw K.E., Levy J.A., Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. USA. 92:1995;7490-7494.
29. Marthas M.L., Miller C.J., Sutjipto S., Higgins J., Torten J., Lohman B.L., Unger R.E., Ramos R.A., Kiyono H., McGhee J.R., Marx P.A., Pedersen N.C. Efficacy of live-attenuated and wholeinactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J. Med. Primatol. 21:1992;99-107.
30. Marx P.A., Compans R.W., Gettie A., Staas J.K., Gilley R.M., Mulligan M.J., Yamshchikov G.V., Chen D., Eldridge J.H. Protection against vaginal SIV transmission with microencapsulated vaccine. Science. 260:1993;1323-1327.
31. Marx P.A., Spira A.I., Gettie A., Dailey P.J., Veazey R.S., Lackner A.A., Mahoney C.J., Miller C.J., Claypool L.E., Ho D.D., Alexander N.J. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2:1996;1084-1089.
32. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207-210.
33. Miller C.J. Mucosal transmissionf of SIV. Curr. Top. Microbiol. Immunol. 188:1994;107-122.
34. Miller C.J., McChesney M.B., Lu X., Dailey P.J., Chutkowski C., Lu D., Brosio P., Roberts B., Lu Y. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J. Virol. 71:1997;1911-1921.
35. Morris C.B., Cheng E., Thanawastien A., Cardenas-Freytag L., Clements J.D. Effectiveness of intranasal immunization with HIV-gp 160 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine. 18:2000;1944-1951.
36. Nathanson N., Hirsch V.M., Mathieson B.J. The role of nonhuman primates in the development of an AIDS vaccine. AIDS. 13:1999;S113-S120.
37. O'Neal C.M., Clements J.D., Estes M.K., Conner M.E. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 72:1998;3390-3393.
38. Rasmussen R.A., Montefiori D.C., Robinson H.L., McClure H.M., Ruprecht R.M. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model lack of original antigenic sin . J. Infect. Dis. 184:2001;1603-1607.
39. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.-W., Karlsson G.B., Sodroski J., Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:1996;6922-6928.
40. Reimann K.A., Li J.T., Voss G., Lekutis C., Tenner-Racz K., Racz P., Lin W., Montefiori D.C., Lee-Parritz D.E., Lu Y., Coliman R.G., Sodroski J., Letvin N.L. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70:1996;3198-3206.
41. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess J.W. Jr., Vasquez G.M., Wiltrout T.A., Chertova E., Grimes M.K., Sattentau Q., Arthur L.O., Henderson L.E., Lifson J.D. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:1998;7992-8001.
42. Snider D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 15:1995;317-348.
43. Sodora D.L., Gettie A., Miller C.J., Marx P.A. Vaginal transmission of SIV assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks . AIDS Res. Hum. Retroviruses. 14:1998;S119-S123.
44. Stephens E.B., Joag S.V., Sheffer D., Liu Z.Q., Zhao L., Mukherjee S., Foresman L., Adany I., Li Z., Pinson D., Narayan O. Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS. J. Med. Primatol. 25:1996;175-185.
45. UNAIDS/WHO, 2000. AIDS epidemic update: December 2000. UNAIDS/WHO, December 2000.
46. Watson A., Ranchalis J., Travis B., McClure J., Sutton W., Johnson P.R., Hu S.-L., Haigwood N.L. Plasma viremia in macaques infected with simian immunodeficiency virus plasma viral load early in infection predicts survival . J. Virol. 71:1997;284-290.
47. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73:1999;8356-8363.